Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced NSCLC Patients With T790M × aflutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 20 Brain Neoplasms 4 NSCLC 3 Adenocarcinoma of Lung 3 Meningeal Carcinomatosis 2 Lung Neoplasms 2 Multiple Primary Lung Cancers 1 Advanced NSCLC Patients With T790M 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03452592 2025-04-03

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Allist Pharmaceuticals, Inc.

Phase 2 Terminated

Advanced NSCLC Patients With T790M

Data powered by HemOnc (CC BY 4.0) Colophon ⚡